NeoGenomics director awarded stock units and options
NeoGenomics Inc. director John P. Kenny reported equity compensation and an option exercise involving company stock.
Rhea-AI Filing Summary
NeoGenomics Inc. director John P. Kenny reported equity compensation and an option exercise involving company stock. He exercised restricted stock units into 5,893 shares of common stock at $0.00 per share and now holds 5,893 common shares directly.
He also received a grant of 15,970 restricted stock units and 11,069 stock options exercisable at $10.52 per share, both scheduled to vest or become exercisable on June 1, 2027. A separate stock option covering 4,171 shares at an exercise price of $11.76 remains outstanding and is scheduled to expire on January 1, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
5,893 shares exercised/converted
Exercise
5 txns
Insider
Kenny John P.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 5,893 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) | 11,069 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 15,970 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,893 | $0.00 | $0.00 |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 15,970 contracts (Direct);
Stock Option (Right to Buy) — 15,240 contracts for 4,171 underlying shares (Direct);
Common Stock — 5,893 shares (Direct)
Footnotes (2)
- F1. Reflects release of restricted stock units that were previously reported on a Form 4.
- F2. Once vested, the shares of common stock are not subject to expiration.
Key Figures
RSUs exercised to common stock: 5,893 shares
Common shares held after transactions: 5,893 shares
New RSU grant: 15,970 units
+5 more
8 metrics
RSUs exercised to common stock
5,893 shares
Converted from restricted stock units on June 1, 2026
Common shares held after transactions
5,893 shares
Direct ownership following June 1, 2026 transactions
New RSU grant
15,970 units
Restricted stock units granted on June 1, 2026
New stock option grant
11,069 options
Options granted June 1, 2026, exercisable from June 1, 2027
New option exercise price
$10.52 per share
Exercise price of 11,069 stock options
Outstanding option exercise price
$11.76 per share
Existing option on 4,171 shares expiring January 1, 2036
Outstanding option underlying shares
4,171 shares
Underlying common shares for existing stock option position
RSU conversion exercised
5,893 shares
Exercise or conversion of derivative security, code M
Key Terms
Restricted Stock Unit, Stock Option (Right to Buy, Exercise or conversion of derivative security, Grant, award, or other acquisition, +1 more
5 terms
Restricted Stock Unit financial
"Reflects release of restricted stock units that were previously reported on a Form 4."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy financial
"Stock Option (Right to Buy) with an exercise price of 11.7600 per share."
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
derivative security financial
"Exercise or conversion of derivative security and derivative transactions reported."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did NeoGenomics (NEO) director John P. Kenny report?
John P. Kenny reported exercising restricted stock units into 5,893 NeoGenomics common shares and receiving new grants of 15,970 restricted stock units plus 11,069 stock options, all held as direct ownership and disclosed as equity-related transactions.
What new equity awards did NeoGenomics (NEO) grant to John P. Kenny?
NeoGenomics granted John P. Kenny 15,970 restricted stock units and 11,069 stock options. The options carry an exercise price of $10.52 per share, and both awards are scheduled to vest or become exercisable on June 1, 2027, subject to their award terms.
What option exercise did John P. Kenny report for NeoGenomics (NEO)?
He reported exercising derivative securities that converted into 5,893 shares of NeoGenomics common stock at $0.00 per share. These shares resulted from previously granted restricted stock units, which were released and are no longer subject to expiration once vested.
What derivative holdings in NeoGenomics (NEO) does John P. Kenny still have outstanding?
John P. Kenny continues to hold stock options linked to 4,171 NeoGenomics common shares with an $11.76 exercise price, expiring January 1, 2036. He also holds newly granted options on 11,069 shares and 15,970 restricted stock units that are scheduled to vest in 2027.
Were there any open‑market buys or sells by John P. Kenny in NeoGenomics (NEO)?
The reported activity consists of equity grants and derivative exercises rather than open‑market purchases or sales. Transactions are coded as option exercises and awards, with no reported open‑market buy or sell codes in this Form 4 disclosure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
